SEARCH

SEARCH BY CITATION

References

  • 1
    Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124: 74757.
  • 2
    Hedner U. Mechanism of action of recombinant activated factor VII: an update. Semin Hematol 2006; 43: S1057.
  • 3
    Hoots WK, Ebbesen LS, Konkle BA, Auerswald GK, Roberts HR, Weatherall J, Ferran JM, Ljung RC. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. The NovoSeven (F7HAEM-1505) Investigators. Haemophilia 2008; 14: 46675.
  • 4
    Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, Serban MA. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 190413.
  • 5
    Robinson AM, McLean KA, Greaves M, Channer KS. Subcutaneous versus intravenous administration of heparin in the treatment of deep vein thrombosis; which do patients prefer? A randomized cross-over study Postgrad Med J 1993; 69: 1156.
  • 6
    McCarthy K, Stewart P, Sigman J, Read M, Keith JC Jr, Brinkhous KM, Nichols TC, Schaub RG. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost 2002; 87: 82430.
  • 7
    Russell KE, Olsen EH, Raymer RA, Merricks EP, Bellinger DA, Read MS, Rup BJ, Keith JC Jr, McCarthy KP, Schaub RG, Nichols TC. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood 2003; 102: 43938.
  • 8
    Berrettini M, Iorio P, Nenci GG, Arcieri P, Mariani G. Subcutaneous factor IX administration to patients with hemophilia B. Am J Hematol 1994; 47: 612.
  • 9
    Gerrard AJ, Austen DE, Brownlee GG. Subcutaneous injection of factor IX for the treatment of haemophilia B. Br J Haematol 1992; 81: 6103.
  • 10
    Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008; 14: 898902.
  • 11
    Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 1006.
  • 12
    Croom KF, McCormack PL. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs 2008; 22: 12136.
  • 13
    von Depka M. Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety. Haemophilia 2005; 11(Suppl. 1): 1823.
  • 14
    World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000; 284: 30435.
  • 15
    Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 73444.
  • 16
    Scharling B, Nielsen GG, Klitgaard T, Skovsted TA, Moss J, Segel S, Larsen LF. Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma. Blood Coagul Fibrinolysis 2007; 18: 67784.
  • 17
    Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957; 17: 23746.
  • 18
    Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000; 17: 127883.
  • 19
    Miekka SI, Jameson T, Singh M, Woolverton C, Lin HM, Krajcik R, MacPhee M, Drohan WN. Novel delivery systems for coagulation proteins. Haemophilia 1998; 4: 43642.
  • 20
    Liles D, Landen CN, Monroe DM, Lindley CM, Read MS, Roberts HR, Brinkhous KM. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Thromb Haemost 1997; 77: 9448.
  • 21
    Mathias M, Khair K, Burgess C, Liesner R. Subcutaneous administration of protein C concentrate. Pediatr Hematol Oncol 2004; 21: 5516.
  • 22
    Sanz-Rodriguez C, Gil-Fernandez JJ, Zapater P, Pinilla I, Granados E, Gómez-G de Soria V, Cano J, Sala N, Fernandez-Ranada JM, Gomez-Gomez N. Long-term management of homozygous protein C deficiency: replacement therapy with subcutaneous purified protein C concentrate. Thromb Haemost 1999; 81: 88790.
  • 23
    Minford AM, Parapia LA, Stainforth C, Lee D. Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate. Br J Haematol 1996; 93: 2156.
  • 24
    Jimenez-Yuste V, Alvarez MT, Martin-Salces M, Quintana M, Rodriguez-Merchan C, Lopez-Cabarcos C, Velasco F, Hernandez-Navarro F. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia 2009; 15: 2039.
  • 25
    Morfini M, Auerswald G, Kobelt RA, Rivolta GF, Rodriguez-Martorell J, Scaraggi FA, Altisent C, Blatny J, Borel-Derlon A, Rossi V. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 5027.
  • 26
    Margaritis P, Roy E, Aljamali MN, Downey HD, Giger U, Zhou S, Merricks E, Dillow A, Ezban M, Nichols TC, High KA. Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood 2009; 113: 36829.
  • 27
    Bolliger D, Szlam F, Molinaro RJ, Escobar MA, Levy JH, Tanaka KA. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. Haemophilia 2010; 16: 5107.
  • 28
    Klintman J, Berntorp E, Astermark J. Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A. Haemophilia 2010; 16: e2105.
  • 29
    Kenet G, Stenmo CB, Blemings A, Wegert W, Goudemand J, Krause M, Schramm W, Kirchmaier C, Martinowitz U. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial. Thromb Haemost 2010; 103: 3519.
  • 30
    Weimer T, Wormsbacher W, Kronthaler U, Lang W, Liebing U, Schulte S. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008; 99: 65967.
  • 31
    Sorensen BB, Karpf D, Groth AV, Bysted BV, Hermit MB, Tranholm M, Bjorn SE, Kinealy K, Zopf D, Bayer RJ, Kalo MS, Stennicke HR. Effect of glycoPEGylation on the pharmacokinetic properties of FVIIa [abstract]. J Thromb Haemost 2007; 5(Suppl. 2): P-T-012.
  • 32
    Yatuv R, Dayan I, Carmel-Goren L, Robinson M, Aviv I, Goldenberg-Furmanov M, Baru M. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia 2008; 14: 47683.
  • 33
    Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899909.
  • 34
    Nicolaisen EM. Long-term follow-up with regard to potential immunogenicity: clinical experience with NovoSeven (recombinant factor VIIa). Haemostasis 1996; 26(Suppl. 1): 98101.
  • 35
    Nicolaisen EM, Hansen LL, Poulsen F, Glazer S, Hedner U. Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use. Thromb Haemost 1996; 76: 2004.
  • 36
    Nicolaisen EM. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis 1998; 9(Suppl. 1): S11923.